|
FDA to Soon Reveal New DMF Screening Process Under GDUFA
Next month, the FDA will begin revealing its criteria for initial completeness tests for Type II active pharmaceutical ingredient (API) drug master files (DMF), an FDA official says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives